HK-660S for adults with primary sclerosing cholangitis
Part of Digestive system clinical trials.
This trial is testing an experimental medicine called HK-660S for people with primary sclerosing cholangitis (PSC), a disease that damages the bile ducts in the liver. The goal is to see if the drug can improve liver health and slow the disease. If you have PSC, you might be able to join if you meet the other health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need a confirmed diagnosis of primary sclerosing cholangitis (PSC).
- You must have a blood test showing high alkaline phosphatase (ALP) at screening.
- If you are able to become pregnant, you and your partner must use an effective birth control method during the study and for 30 days after.
- You cannot have other major liver diseases (like fatty liver, viral hepatitis, or autoimmune hepatitis).
- You cannot have a history of alcohol abuse in the past 5 years, and you must not drink more than about 1-2 units of alcohol a day.
- You must not have certain medical conditions (like serious heart disease, uncontrolled thyroid issues, or severe kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
This trial tests whether a fecal microbiota transplant (a procedure that puts healthy bacteria from a donor's stool into your gut) can help people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if this treatment can slow the disease and improve liver health.
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
Hear when a new Primary Sclerosing Cholangitis (PSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.